GlobeNewsWire
26 Sept 2026, 00:42 UTC · 1h ago
Verdict
Headline takes no side. We score AARD −1.00 across two claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
A securities class action lawsuit alleges Aardvark Therapeutics misled investors regarding the safety and commercial prospects of its ARD-101 drug.
Priced inmentions a class action lawsuit has already been filed
More negative than 86% of claims this week
The deadline for investors to move the Court to serve as lead plaintiff in the Aardvark class action is October 13, 2026.
New
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
So whatThe window for lead plaintiff appointment closes in approximately 18 days.
More negative than 64% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities class action lawsuit alleging materially false and misleading statements regarding the safety and prospects of its ARD-101 product.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
—
AARD hasn't traded since this ran. Last close $5.06 (Sep 25); the reaction starts at the next open.
AARD chart →
